Tango Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
Tango Therapeutics, Inc. (TNGX) reported Basic Shares Outstanding (Weighted Average) of 149.88 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 149.88M shares, a 35.58% increase year-over-year.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 143.58M shares, a 30.17% increase year-over-year.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 132.38M shares, a 20.41% increase year-over-year.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 110.97M shares, a 2.27% increase year-over-year.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 116.17M shares, a 6.35% increase from fiscal 2024.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 109.23M shares, a 15.50% increase from fiscal 2023.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 94.57M shares, a 7.69% increase from fiscal 2022.
- Tango Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 87.82M shares, a 41.40% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 149.88M shares 10-Q · filed 2026-08-11 | 148.66M shares 10-Q · filed 2026-08-11 | 141.94M shares derived: average of 3 quarters · filed 2026-08-11 | 134.20M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 143.58M shares 10-Q · filed 2026-05-13 | 137.98M shares derived: average of 2 quarters · filed 2026-05-13 | 128.97M shares derived: average of 3 quarters · filed 2026-05-13 | 124.37M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 132.38M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 121.67M shares derived: average of 2 quarters · filed 2026-03-05 | 117.96M shares derived: average of 3 quarters · filed 2026-08-11 | 116.17M shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 110.97M shares 10-Q · filed 2025-11-04 | 110.75M shares derived: average of 2 quarters · filed 2026-08-11 | 110.76M shares 10-Q · filed 2025-11-04 | 110.44M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 110.54M shares 10-Q · filed 2026-08-11 | 110.49M shares 10-Q · filed 2026-08-11 | 110.26M shares derived: average of 3 quarters · filed 2026-08-11 | 109.82M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 110.30M shares 10-Q · filed 2026-05-13 | 110.12M shares derived: average of 2 quarters · filed 2026-05-13 | 109.58M shares derived: average of 3 quarters · filed 2026-05-13 | 109.26M shares derived: average of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | 109.94M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 109.22M shares derived: average of 2 quarters · filed 2026-03-05 | 108.92M shares derived: average of 3 quarters · filed 2026-03-05 | 109.23M shares 10-K · filed 2026-03-05 |
| 2024-09-30 | 108.51M shares 10-Q · filed 2025-11-04 | 108.41M shares derived: average of 2 quarters · filed 2025-11-04 | 108.99M shares 10-Q · filed 2025-11-04 | 107.37M shares derived: average of 4 quarters · filed 2026-03-05 |
| 2024-06-30 | 108.31M shares 10-Q · filed 2025-08-05 | 108.69M shares 10-Q · filed 2025-08-05 | 106.99M shares derived: average of 3 quarters · filed 2026-03-05 | 104.50M shares derived: average of 4 quarters · filed 2026-03-05 |
| 2024-03-31 | 108.17M shares 10-Q · filed 2025-05-12 | 106.33M shares derived: average of 2 quarters · filed 2026-03-05 | 103.23M shares derived: average of 3 quarters · filed 2026-03-05 | 99.51M shares derived: average of 4 quarters · filed 2026-03-05 |
| 2023-12-31 | 104.49M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 100.76M shares derived: average of 2 quarters · filed 2026-03-05 | 96.62M shares derived: average of 3 quarters · filed 2026-03-05 | 94.57M shares 10-K · filed 2026-03-05 |
| 2023-09-30 | 97.03M shares 10-Q · filed 2024-11-06 | 92.69M shares derived: average of 2 quarters · filed 2024-11-06 | 91.27M shares 10-Q · filed 2024-11-06 | 90.31M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | 88.35M shares 10-Q · filed 2024-08-07 | 88.28M shares 10-Q · filed 2024-08-07 | 88.07M shares derived: average of 3 quarters · filed 2025-02-27 | 88.03M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | 88.19M shares 10-Q · filed 2024-05-08 | 87.93M shares derived: average of 2 quarters · filed 2025-02-27 | 87.92M shares derived: average of 3 quarters · filed 2025-02-27 | 87.90M shares derived: average of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | 87.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 87.78M shares derived: average of 2 quarters · filed 2025-02-27 | 87.80M shares derived: average of 3 quarters · filed 2025-02-27 | 87.82M shares 10-K · filed 2025-02-27 |
| 2022-09-30 | 87.89M shares 10-Q · filed 2023-11-08 | 87.87M shares derived: average of 2 quarters · filed 2023-11-08 | 87.87M shares 10-Q · filed 2023-11-08 | 87.91M shares derived: average of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | 87.84M shares 10-Q · filed 2023-08-07 | 87.78M shares 10-Q · filed 2023-08-07 | 87.92M shares derived: average of 3 quarters · filed 2023-08-07 | 83.48M shares derived: average of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | 87.67M shares 10-Q · filed 2023-05-09 | 87.96M shares derived: average of 2 quarters · filed 2023-05-09 | 82.02M shares derived: average of 3 quarters · filed 2023-05-09 | 73.65M shares derived: average of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | 88.24M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | 79.20M shares derived: average of 2 quarters · filed 2023-03-27 | 68.97M shares derived: average of 3 quarters · filed 2023-03-27 | 62.11M shares 10-K · filed 2023-03-27 |
| 2021-09-30 | 70.16M shares 10-Q · filed 2022-11-10 | 59.34M shares derived: average of 2 quarters · filed 2022-11-10 | 53.40M shares 10-Q · filed 2022-11-10 | |
| 2021-06-30 | 48.52M shares 10-Q · filed 2022-08-10 | 45.09M shares 10-Q · filed 2022-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |